首页> 外文期刊>BMC Hematology >Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study
【24h】

Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study

机译:抗凝患者对疾病的看法,对抗凝治疗的信念以及与依从性的关系:新型口服抗凝治疗的影响–转换研究的研究方案:一项前瞻性队列研究

获取原文
           

摘要

BackgroundAnticoagulant therapy is prescribed for millions of patients worldwide for the prevention and treatment of both arterial and venous thrombosis. Historically, only vitamin K antagonists have been available for clinicians to prescribe. The anticoagulation landscape is changing. The recent availability of the novel oral anticoagulants overcome many of the disadvantages associated with vitamin K antagonists. However the lack of formal monitoring and clinic follow-up is a concern for clinicians, as medication adherence is being assumed, which is known to decline in patients prescribed medications for chronic conditions. The switching study is a programme of work investigating the association between medication adherence and patient’s beliefs about anticoagulation therapy (warfarin and subsequently novel oral anticoagulants), together with beliefs about their illness and anticoagulation related quality of life. Methods/designThe anticoagulation database at King’s College Hospital will be interrogated and two groups of patients will be identified; those with a time in therapeutic range on warfarin of ≥75?% and those DiscussionThe results from the switching study will be used to develop a clinical pathway to support patient’s prescribed novel oral anticoagulant therapy long-term.
机译:背景技术为全世界预防和治疗动脉血栓形成和静脉血栓形成的患者,已规定了抗凝治疗方法。从历史上看,只有维生素K拮抗剂可供临床医生开处方。抗凝领域正在发生变化。新型口服抗凝剂的最新可用性克服了与维生素K拮抗剂相关的许多缺点。然而,由于正在假设药物依从性,因此缺乏正式的监测和临床随访是临床医生关注的问题,已知这会降低长期病患者处方药物的使用率。转换研究是一项工作计划,旨在研究药物依从性与患者对抗凝治疗的信念(华法林及随后的新型口服抗凝剂)之间的联系,以及对其疾病和与抗凝相关的生活质量的信念。方法/设计将询问国王学院医院的抗凝数据库,并确定两组患者;那些在华法林治疗时间≥75%的患者以及这些讨论转换研究的结果将用于开发一条临床途径,以长期支持患者处方的新型口服抗凝治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号